Neuroendocrine: Clinical Trials

5 trials for Neuroendocrine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 unknown, 1 terminated. 4 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Terminated 1, Unknown 1
Phase 13Unknown 2, Terminated 1

Follow Neuroendocrine: new trials by email Literature Review of Neuroendocrine trials Research Report on Neuroendocrine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. - Neuroendocrine, Neuroendocrine Tumor
Phase 1 / Phase 2UnknownOchsner Health System2502014-03-012014-01-17
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
JI-101, Everolimus - Cancer, Neuroendocrine
Phase 1 / Phase 2TerminatedUniversity of Utah192010-09-012014-10-06
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
MK-2206 - PANCREAS, Neuroendocrine
Phase 2CompletedMemorial Sloan Kettering Cancer Center112010-07-012016-02-18
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Everolimus - Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma
Phase 2CompletedNovartis Pharmaceuticals732009-06-242019-01-25
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
Seneca Valley Virus (biological agent) - Carcinoid, Neuroendocrine
Phase 1UnknownNeotropix602006-04-012010-02-25

Narrower conditions

Carcinoid Tumor (3)  ·  Neuroendocrine Tumors (3)  ·  Adenoma, Islet Cell (1)  ·  Apudoma (1)  ·  Carcinoma (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Colonic Neoplasms (1)  ·  Glioblastoma (1)  ·  Medulloblastoma (1)  ·  Neoplasms (1)  ·  Neuroblastoma (1)  ·  Ovarian Neoplasms (1)  ·  Retinoblastoma (1)  ·  Rhabdomyosarcoma (1)  ·  Rhabdomyosarcoma, Alveolar (1)

Broader conditions

Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Germ Cell and Embryonal (4)  ·  Neoplasms, Nerve Tissue (4)  ·  Neuroectodermal Tumors (4)  ·  Adenocarcinoma (3)  ·  Neoplasms by Site (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Carcinoma (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Endocrine Gland Neoplasms (2)  ·  Endocrine System Diseases (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)

Interventions

Everolimus (2)  ·  1-(1-(2-amino-pyridin-4-ylmethyl)-1H-indol-4-yl)-3-(5-bromo-2-methoxyphenyl)urea (1)  ·  Biological Factors (1)  ·  MK 2206 (1)

Sponsors

Memorial Sloan Kettering Cancer Center (1)  ·  Neotropix (1)  ·  Novartis Pharmaceuticals (1)  ·  Ochsner Health System (1)  ·  University of Utah (1)

Countries

United States (4)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Spain (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Diane Reidy-Lagunes, MD,MS (1)  ·  Rudin Charles, MD, PhD (1)  ·  Sunil Sharma, MD (1)

Results publications

PMID 18391430